Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 803-816

  Towner, William J ^a   Cassetti, Isabel ^b   Domingo, Pere ^c   Nijs, Steven ^d   Kakuda, Thomas N ^e   Vingerhoets, Johan ^d   Woodfall, Brian ^d  

^a KAISER PERMANENTE   (United States)

^b Helios Salud ^*  (Argentina)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d TIBOTEC BVBA   (Belgium)

^e Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LIVER DISEASE; NAUSEA; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77957339788     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1651     Document Type: Review

References (72)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
3. US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. (Updated 1 December 2009. Accessed 25 January 2010.) Available from http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf
4. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
5. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIVinfected adults in Europe. (Updated November 2009. Accessed 25 January 2010.) Available from http://www. europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV-Infected- Adults.pdf
6. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448.
7. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835-838.
8. Bristol-Myers Squibb Company. Sustiva® (efavirenz) US prescribing information. (Updated March 2009. Accessed 10 April 2009.) Available from http://packageinserts.bms.com/pi/pi-sustiva.pdf
9. Boehringer Ingelheim Ltd. Viramune® (nevirapine) summary of product characteristics. (Updated 18 February 2009. Accessed 10 April 2009.) Available from http://emc.medicines.org.uk/medicine/322/SPC/Viramune%20Tablets/
10. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
11. Andries K, de Béthune M-P, Ludovici D, et al. R165335- TMC125, a novel non nucleoside reverse transferase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2000, Toronto, ON, Canada. Abstract 1840.
12. de Béthune M-P, Hertogs K, Azijn H, et al. R165335- TMC125, a third generation non nucleoside reverse transcriptase inhibitor (NNRTI), inhibits 98% of more than 2,000 recombinant HIV clinical isolates at 100nM. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2000, Toronto, ON, Canada. Abstract 1841.
13. Tibotec Inc. INTELENCE™ (etravirine) prescribing information. (Updated August 2009. Accessed 16 November 2009.) Available from www.intelence-info.com/intelence/assets/pdf/INTELENCE-PI.pdf
14. European Medicines Agency. INTELENCE (etravirine): summary of product characteristics. (Updated 26 July 2010. Accessed 16 November 2009.) Available from www.emea.europa.eu/humandocs/Humans/EPAR/intelence/intelence.htm
15. Das K, Clark AD, Jr., Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47:2550-2560.
16. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
17. Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a Phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis 2008; 47:969-978.
18. The TMC-125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007; 21:F1-F10.
19. Cohen CJ, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1- infected patients: 48-week results of a Phase IIb trial. AIDS 2009; 23:423-426.
20. Kakuda TN, Schöller-Gyüre M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1- infected patients. Antivir Ther 2008; 13:655-661.
21. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9:883-896.
22. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV- 1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
23. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
24. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 790.
25. Johnson M, Campbell T, Clotet B, et al. DUET-2: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 791.
26. Katlama C, Gatell J, Molina E, et al. Pooled 24-week results of DUET-1 and -2: efficacy of TMC125 in treatment-experienced HIV-1-infected patients. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Abstract P7 3/16.
27. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23:2289-2300.
28. Clumeck N, Clotet B, Johnson M, et al. Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract P023.
29. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
30. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
31. Cahn P, Molina JM, Towner W, et al. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR). 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUPE0047.
32. Kakuda TN, Peeters M, Corbett C, et al. Pharmacokinetics and pharmacodynamics of etravirine in treatment-experienced HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Meeting of the Infectious Diseases Society of America. 25-28 October 2008, Washington, DC, USA. Abstract H-4056.
33. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
34. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
35. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
36. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475.
37. Hawkins N, Davies A. An indirect comparison of two new HIV treatments for treatment-experienced patients. 30th Annual Meeting of the Society for Medical Decision Making. 18-22 October 2008, Philadelphia, PA, USA. Abstract 30BMA.
38. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-1449.
39. Florence E, De Wit S, Castagna A, et al. Antiretroviral treatment use and HIV RNA suppression rates for 941 European patients in the etravirine early access programme. 9th International Congress on Drug Therapy and HIV Infection. 9-13 November 2008 Glasgow, UK. Abstract 36.
40. Imaz A, Del Saz SV, Ribas MA, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:382-386.
41. Katlama C, Campbell T, Schechter M, et al. Incidence and severity of nervous system and psychiatric events are similar with etravirine (TMC125, ETR) versus placebo: pooled 48-week data from the Phase III DUET studies. 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUPE0056.
42. Mills A, Grinsztejn B, Katlama C, et al. The incidence of rash observed with the NNRTI etravirine (TMC125; ETR) in the Phase III DUET trials using pooled 48-week data. 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUPE0059.
43. Peeters M, Janssen K, Kakuda TN, et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother 2008; 42:757-765.
44. Trottier B, Johnson M, Katlama C, et al. Pooled 48-week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients. 17th Annual Canadian Conference on HIV/AIDS Research. 24-27 April 2008, Montreal, QC, Canada. Abstract P167.
45. Lalezari J, Leider J, Wilkin T, et al. Hepatic safety and tolerability of etravirine in HIV-1-infected treatment-experienced patients: pooled analysis of the DUET-1 and DUET-2 trials. 59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 October-4 November 2008, San Francisco, CA, USA. Abstract 347.
46. Clotet B, Katlama C, Lazzarin A, et al. Safety and tolerability of etravirine in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract P272.
47. Raoof A, Lachau-Durand S, Verbeeck J, et al. Etravirine (ETR; TMC125) has no effect on fetal development in rats and rabbits. 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUPE0013.
48. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009; 23:434-435.
49. Izurieta P, Kakuda TN, Clark A, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-infected women. 12th European AIDS Conference, 11-14 November 2009, Cologne, Germany. Abstract PE4.1/6.
50. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the DUET studies. AIDS 2010; 24:503-514.
51. Benhamida J, Chappey C, Coakley E, Parkin N. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Antivir Ther 2008; 13 Suppl 3:A142.
52. Cotte L, Trabaud MA, Tardy JC, et al. Prediction of the virological response to etravirine in clinical practice: comparison of three genotype algorithms. J Med Virol 2009; 81:672-677.
53. Schöller-Gyüre M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 2008; 28:1215-1222.
54. Schöller-Gyüre M, Kakuda T, Van Solingen-Ristea R, et al. Bioavailability of the 100mg etravirine tablet dispersed in water and of the 25mg pediatric tablet formulation. 17th International AIDS Conference. 3-8 August 2008. Mexico City, Mexico, Abstract MOPE0184.
55. Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in once-daily and twice-daily regimens in HIV-1-negative volunteers. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract A-1427.
56. Lalezari J, DeJesus E, Osiyemi O, et al. Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naive HIV-1-infected adults. 9th International Congress on Drug Therapy and HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract O413.
57. Konigs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract S-167.
58. Schöller-Gyüre M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48:561-574.
59. Schöller-Gyüre M, Raoof A, Mannens G, et al. Mass balance of 14C-labelled TMC125 in healthy volunteers. 8th International Workshop on Clinical Pharmacology of HIV Therapy. 16-18 April 2007, Budapest, Hungary. Abstract 78.
60. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52:4228-4232.
61. Kakuda TN, Schöller-Gyüre M, Woodfall B. TMC125 in combination with other medications: summary of drug-drug interaction studies. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Abstract PL5.2.
62. Davis J, Schöller-Gyüre M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Abstract P4.3/02.
63. Schöller M, Hoetelmans R, Bollen S, et al. No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract WePe3.3C16.
64. Harris M, Zala C, Ramirez S, et al. Pharmacokinetics and safety of adding TMC125 to stable regimens of saquinavir, lopinavir, ritonavir, and NRTI in HIV+ adults. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 575b.
65. Ramanathan S, Kakuda TN, Mack R, West S, Kearney BP. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008; 13:1011-1017.
66. Schöller-Gyüre M, Debroye C, Vyncke V, et al. Effect of TMC125 on sildenafil pharmacokinetics. 7th International Workshop of Clinical Pharmacology. 20-22 April 2006, Lisbon, Portugal. Abstract 45.
67. Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEA106.
68. Schöller-Gyüre M, Kakuda TN, Bollen S, et al. No pharmacokinetic interaction between TMC125 (etravirine; ETR) and paroxetine in HIV-negative volunteers. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Abstract P4.3/01.
69. Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol 2008; 66:508-516.
70. Schöller-Gyüre M, Kakuda T, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and co-administered in HIV-negative volunteers. Antivir Ther 2007; 12:789-796.
71. Maas B, Kerr T, Fairbairn N, Montaner J, Wood E. Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opin Drug Metab Toxicol 2006; 2:533-543.
72. Schöller-Gyüre M, Van den Brink W, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008; 48:322-329.